• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Parexel Reports 33% Drop in Income, Ups Guidance

Parexel Reports 33% Drop in Income, Ups Guidance

January 26, 2010
CenterWatch Staff

Parexel’s second quarter net income fell 33% to $3.5 million, or $0.06 per diluted share, compared with the same quarter last year.

Parexel increased its fiscal year 2010 service revenue forecast from previously issued guidance. The contract research organization (CRO )expects service revenue in the range of $1.125 to $1.145 billion (up from $1.115 to $1.145 billion) with earnings per diluted share to be in the range of $0.66 to $0.72 (up from $0.60 to $0.70).

For the three months ended Dec. 31, 2009, service revenue increased 3.2% to $284.7 million compared with $275.8 million in the prior year period, but this increase was a result of the positive impact of foreign exchange to the tune of $14 million. Excluding the foreign exchange dollars, revenue decreased 2% from the second quarter 2008. Year-to-date service revenue increased 1% to $544.5 million compared with $538.9 million in the prior year period.  

The company incurred $14.3 million in restructuring fees during its second quarter, as well as a $6.1-million charge for the impairment of an investment. The CRO expects to record an additional $14 million in restructuring charges during the third quarter of fiscal year 2010, equating to approximately $0.14 per diluted share.  

“Our results for the December quarter capped a solid and positive finish to a challenging year,” said Parexel chairman and CEO Josef von Rickenbach in a statement. “A strong performance on the new business front drove substantive backlog gains, with increases across all three reporting segments.  We also continued to improve operating margins, and expect further margin expansion in the coming quarters, as the benefits of restructuring activities and other productivity and efficiency initiatives begin to take hold."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing